CClinicalTrials.gg
CompletedNCT02796625APBUpdated Aug 11, 2021Results posted

Alpha as a Predictive Biomarker

An interventional study of Painful Stimuli in Pain, sponsored by University of Maryland, Baltimore. Completed at 1 site in United States. Open to participants aged 21 Years to 44 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-08-11.

Sponsored by University of Maryland, Baltimore · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
21 Years to 44 Years
Sex
All
01

Study summary

The investigators will use non-invasive recordings of brain activity to measure pain as a proxy to self-report. Participants will undergo testing for about 3 hours on two separate days. The testing will involve experiencing painful heat.

Read the detailed description

Neurophysiological investigations of pain have suggested that electroencephalograph (EEG) measures of peak alpha frequency might provide a means of pain assessment. In healthy subjects, increased peak alpha frequency is strongly correlated with pain self-reports after exposure to acute noxious heat. Conversely, chronic pain patients compared to healthy control display decreased peak alpha frequencies higher in alpha power. Measures of peak alpha frequency also show a negative relationship with disease duration, suggesting that peak alpha frequency may not only index ongoing pain but also disease progression. The overall aim is to determine the predictive accuracy, reliability, and specificity of EEG alpha activity in acute pain and a model of neuropathic pain in healthy subjects.

02

Conditions studied

  • Pain

Keywords

  • EEG
  • healthy subjects
03

In context

Lead sponsor

University of Maryland, Baltimore is the lead sponsor of 687 studies on the registry; 130 are open to participants now.

Of its 90 completed or terminated interventional studies of FDA-regulated products, 63 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 44 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Able to speak, read, and write English
  • Between 21 and 44 years of age
  • Able to understand and willing to comply with all study procedures and is available for the duration of the study
  • Free of an acute or chronic pain condition
  • Not history of psychiatric or neurologic condition

Exclusion criteria

Exclusion Criteria:

  • Unable to undergo EEG, assessed on an individual basis
  • History of unstable major psychiatric disorder (self-report)
  • History of chronic pain (self-report)
  • More than 14 alcoholic drinks per week on average (self-report)
  • Active [within 6 months] substance or alcohol abuse (self-report and urine toxicology)
  • Use of opioids (self-report and urine toxicology)
  • History of major depressive disorder (self-report)
  • Pregnant or Lactating (women only), based on (self-report and urine test)
  • Anything that, in the opinion of the investigator, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study
  • Uncontrolled (systolic blood pressure > 175 mmHg or diastolic blood pressure >105 mmHg) or unstable hypertension
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Painful Stimuli

    Participants will be exposed to painful heat

    Other: Painful Stimuli

Interventions

  • OtherPainful Stimuli

    warm or painful heat administration

06

What researchers measure

Primary outcomes

  1. Peak Alpha Frequency (Hz)

    The highest power of EEG-based alpha activity in the 8-12Hz frequency range, calculated using the center of gravity method.

    Time frame: pain-free and pain states at the baseline visit

Secondary outcomes

  1. Alpha Wave Activity Reliability

    Time frame: alpha activity at pain-free and pain states, assessed at a second visit following the first visit by at least 3 week

07

Results

Posted Aug 11, 2021

Participant flow

Participant flow — Overall Study
MilestonePainful Stimuli
Started80
Completed61
Not completed19

Outcome measures

PrimaryPeak Alpha Frequency (Hz)

The highest power of EEG-based alpha activity in the 8-12Hz frequency range, calculated using the center of gravity method.

Time frame:
pain-free and pain states at the baseline visit
Reported as:
Mean · frequency (Hz)
Peak Alpha Frequency (Hz)
frequency (Hz)Painful Stimuli
Peak Alpha Frequency (Hz)10.04 ± 0.20
SecondaryAlpha Wave Activity Reliability
Time frame:
alpha activity at pain-free and pain states, assessed at a second visit following the first visit by at least 3 week
Reported as:
Number · Spearman rho
Alpha Wave Activity Reliability
Spearman rhoPainful Stimuli
Alpha Wave Activity Reliability.81

Adverse events

Collected over 10 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Painful Stimuli0/61 (0%)0/61 (0%)0/61 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Painful Stimuli
<=18 years0
Between 18 and 65 years61
>=65 years0
Age, Continuous
Age, Continuous(years)Painful Stimuli
Mean27.8 (21 to 42)
Sex: Female, Male
Sex: Female, Male(Participants)Painful Stimuli
Female30
Male31
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Painful Stimuli
Region of Enrollment
Region of Enrollment(participants)Painful Stimuli
United States61
08

Study locations

1 site
  • University of Maryland School of Dentistry
    Baltimore, Maryland 21201, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 6, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02796625
Lead sponsor
University of Maryland, Baltimore
Collaborators
Purdue Pharma LP
Responsible party
David Seminowicz (Associate Professor, Department of Neural and Pain Sciences, University of Maryland, Baltimore) — Principal investigator
First posted
Jun 13, 2016
Start date
Jul 2016
Primary completion
Jul 2018
Completion
Jul 2018
Results posted
Aug 11, 2021
Last update
Aug 11, 2021

Study contacts

David A Seminowicz, PhD
principal investigator · University of Maryland Dental School

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion